Vol 72, No 4 (2021)
Clinical vignette
Published online: 2021-05-31

open access

Page views 1241
Article views/downloads 768
Get Citation

Connect on Social Media

Connect on Social Media

Pembrolizumab-induced diabetes

Rumaisa Banatwalla1, Omar Zuhair Kirresh2, Fahad Wali Ahmed2
Pubmed: 34057191
Endokrynol Pol 2021;72(4):414-415.

Abstract

Not required for Clinical Vignette.

Article available in PDF format

View PDF Download PDF file

References

  1. Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports. PLoS One. 2016; 11(7): e0160221.
  2. Ishida M, Iwai Y, Tanaka Y, et al. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol Lett. 2002; 84(1): 57–62.
  3. Colli ML, Hill JLE, Marroquí L, et al. PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-α and-γ via IRF1 induction. EBioMedicine. 2018; 36: 367–375.
  4. Clotman K, Janssens K, Specenier P, et al. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus. J Clin Endocrinol Metab. 2018; 103(9): 3144–3154.
  5. Stamatouli AM, Quandt Z, Perdigoto AL, et al. Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes. 2018; 67(8): 1471–1480.
  6. Eshet Y, Baruch EN, Shapira-Frommer R, et al. Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case-Control Study. Cancer Immunol Res. 2018; 6(12): 1453–1458.